title: Technology evaluation: PROSTVAC, Therion.
abstract: Therion Biologics is developing PROSTVAC, an immunotherapeutic vaccine that targets prostate-specific antigen, for the potential treatment of prostate cancer. In February 2000, phase II trials had commenced. By October 2001, the drug was undergoing four phase II trials.
authors.affiliation: Department of Urology, University of Lübeck Medial School, Germany. doehn@medinf.mu-luebeck.de
authors.forename: Christian
authors.initials: C
authors.lastname: Doehn
authors.forename: Dieter
authors.initials: D
authors.lastname: Jocham
mesh_terms: D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D013673:Technology Assessment, Biomedical
chemical_list: D019496:Cancer Vaccines